Novus Biologicals products are now on bio-techne.com

Recombinant Human CCL21/6Ckine Protein

Images

 
There are currently no images for CCL21/6Ckine (366-6C).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price
Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

Recombinant Human CCL21/6Ckine Protein Summary

Details of Functionality
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CCR7. The ED50 for this effect is 3-15 ng/mL.
Source
E. coli-derived human CCL21/6Ckine protein
Ser24-Pro134
Accession #
N-terminal Sequence
Ser24
Protein/Peptide Type
Recombinant Proteins
Gene
CCL21
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Bioactivity2
Theoretical MW
12 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
16-17 kDa, reducing conditions
Publications
Read Publications using
366-6C in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CCL21/6Ckine Protein

  • 6Ckine
  • 6CkineSmall-inducible cytokine A21
  • Beta-chemokine exodus-2
  • CCL21
  • chemokine (C-C motif) ligand 21
  • CKb9
  • exodus-2
  • member 21
  • SCYA21
  • SCYA21MGC34555
  • secondary lymphoid tissue chemokine
  • SLC
  • SLCSecondary lymphoid-tissue chemokine
  • TCA-4

Background

CCL21, also known as 6Ckine, TCA-4, SLC, Exodus-2, and A21, is a 12 kDa homeostatic chemokine that plays an important role in adaptive immune responses and inflammation (1). Unlike other CC chemokines, human CCL21 has a 37 amino acid (aa) C-terminal extension which mediates its attachment to carbohydrate structures and extracellular matrix components (2, 3). Mature human CCL21 shares 71% and 66% aa sequence identity with mouse and rat CCL21, respectively (4‑6). Both human and mouse CCL21 signal through the chemokine receptor CCR7, while mouse CCL21 additionally can signal through CXCR3 (7). CCL21 is constitutively presented on initial lymphatic vessels, high endothelial venules (HEV), and lymph node dendritic cells (DC) (8‑10). Immobilized CCL21 promotes the docking of DC to lymphatic vessels and the retention of T cells by lymph node DC, resulting in T cell priming for activation (8, 9). DC interaction with the anchored chemokine can induce CCL21 cleavage and release of an 8 kDa fragment that lacks the C-terminal extension (10). During chronic inflammation or tissue damage, CCL21 is up‑regulated on local vascular endothelial cells, macrophages, T cells, and neurons (11‑14). In these settings, it promotes fibrosis, inflammatory cytokine production, and neuropathic pain (12‑14). The soluble chemokine is elevated in rheumatoid arthritis synovial fluid and in the serum of coronary artery disease patients (11, 13). CCL21 has been shown to exert either angiogenic or angiostatic effects (11, 15, 16). These effects, in combination with the ability of CCL21 to attract immune suppressor cells (Treg and MDSC) to a tumor site can have positive or negative effects on tumor progression (16, 17).
  1. Forster, R. et al. (2008) Nat. Rev. Immunol. 8:362.
  2. Yang, B.G. et al. (2007) J. Immunol. 179:4376.
  3. Rey-Gallardo, A. et al. (2010) Glycobiology 20:1139.
  4. Hromas, R. et al. (1997) J. Immunol. 159:2554.
  5. Nagira, M. et al. (1997) J. Biol. Chem. 272:19518.
  6. Hedrick, J.A. and A. Zlotnik (1997) J. Immunol. 159:1589.
  7. Jenh, C. et al. (1999) J. Immunol. 162:3765.
  8. Tal, O. et al. (2011) J. Exp. Med. 208:2141.
  9. Friedman, R.S. et al. (2006) Nat. Immunol. 7:1101.
  10. Schumann, K. et al. (2010) Immunity 32:703.
  11. Pickens, S.R. et al. (2012) Arthritis Rheum. 64:2471.
  12. Sakai, N. et al. (2006) Proc. Natl. Acad. Sci. USA 103:14098.
  13. Damas, J.K. et al. (2007) Arterioscler. Thromb. Vasc. Biol. 27:614.
  14. Biber, K. et al. (2011) EMBO J. 30:1864.
  15. Soto, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:8205.
  16. Vicari, A.P. et al. (2000) J. Immunol. 165:1992.
  17. Shields, J.D. et al. (2010) Science 328:749.

Customers Who Viewed This Item Also Viewed...

440-M3
Species: Mu
Applications: BA, BA
MAB197
Species: Hu
Applications: CyTOF-reported, Dual ISH-IHC, Flow, ICC, IHC, Neut
NBP3-12223
Species: Hu, Pm, Rt
Applications: ELISA, ICC/IF, IHC, IHC-P, IP, WB
NBP1-72042
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, PEP-ELISA, WB
350-NS
Species: Fe, Hu, RM
Applications: BA, BA
NBP1-19371
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
DM3A00
Species: Hu
Applications: ELISA
NBP1-49045
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
DCP00
Species: Hu
Applications: ELISA
DIP100
Species: Hu
Applications: ELISA
DRN00B
Species: Hu
Applications: ELISA
MAB172
Species: Hu
Applications: CyTOF-ready, Flow, IHC, Neut
NBP2-37447
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, WB
202-IL
Species: Hu
Applications: BA
366-6C
Species: Hu
Applications: Bioactivity

Publications for CCL21/6Ckine (366-6C)(33)

We have publications tested in 2 confirmed species: Human, Virus.

We have publications tested in 4 applications: Binding Assay, Bioassay, CAR-T (Bioassay), ELISA (Standard).


Filter By Application
Binding Assay
(1)
Bioassay
(32)
CAR-T (Bioassay)
(1)
ELISA (Standard)
(1)
All Applications
Filter By Species
Human
(32)
Virus
(1)
All Species
Showing Publications 1 - 10 of 33. Show All 33 Publications.
Publications using 366-6C Applications Species
Seetharaman, A;Christopher, V;Dhandapani, H;Jayakumar, H;Dhanushkodi, M;Bhaskaran, N;Rajaraman, S;Ranganathan, R;Sunder Singh, S;Vijayakumar, V;Rajamanickam, A;Suri, A;Jagadish, N;Rajkumar, T;Ramanathan, P; Optimization and Validation of a Harmonized Protocol for Generating Therapeutic-Grade Dendritic Cells in a Randomized Phase II Clinical Trial, Using Two Varied Antigenic Sources Vaccines 2024-01-23 [PMID: 38400096] (Bioassay, Human) Bioassay Human
Z Su, J Brooks, J Pelker, T Andreyeva, H Sobon, R Gifford, M Powers, J Wang, C Dower, M Hegen, D Messing, AD Sheehan, JJ Brennan Studies with neutralizing antibodies suggest CXCL8-mediated neutrophil activation is independent of C-C motif chemokine receptor-like 2 (CCRL2) ligand binding function PLoS ONE, 2023-01-20;18(1):e0280590. 2023-01-20 [PMID: 36662882] (Bioassay, Human) Bioassay Human
EP Brandum, AS Jørgensen, MB Calvo, K Spiess, FC Peterson, Z Yang, BF Volkman, CT Veldkamp, MM Rosenkilde, CK Goth, GM Hjortø Selective Boosting of CCR7-Acting Chemokines; Short Peptides Boost Chemokines with Short Basic Tails, Longer Peptides Boost Chemokines with Long Basic Tails International Journal of Molecular Sciences, 2022-01-26;23(3):. 2022-01-26 [PMID: 35163323] (Bioassay, Human) Bioassay Human
T Radaszkiew, M Nosková, K Gömöryová, O Vondálová, KA Radaszkiew, M Picková, R Víchová, T Gybe?, K Kaiser, L Demková, L Ku?erová, T Bárta, D Pot?šil, Z Zdráhal, K Sou?ek, V Bryja RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy Elife, 2021-10-27;10(0):. 2021-10-27 [PMID: 34702444] (Bioassay, Human) Bioassay Human
K Kurowarabe, M Endo, D Kobayashi, H Hayasaka CXCL12-stimulated lymphocytes produce secondary stimulants that affect the surrounding cell chemotaxis Biochemistry and Biophysics Reports, 2021-09-07;28(0):101128. 2021-09-07 [PMID: 34527817] (Bioassay, Human) Bioassay Human
H Dhandapani, H Jayakumar, A Seetharama, SS Singh, S Ganeshraja, N Jagadish, A Suri, R Thangaraja, P Ramanathan Dendritic cells matured with recombinant human sperm associated antigen 9 (rhSPAG9) induce CD4+, CD8+ T cells and activate NK cells: a potential candidate molecule for immunotherapy in cervical cancer Cancer Cell International, 2021-09-07;21(1):473. 2021-09-07 [PMID: 34493268] (Bioassay, Human) Bioassay Human
ML Capitano, A Jaiswal, HE Broxmeyer, Y Pride, S Glover, FG Amlashi, A Kirby, G Srinivasan, EA Williamson, D Mais, R Hromas A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease PLoS ONE, 2021-07-01;16(7):e0252805. 2021-07-01 [PMID: 34197491] (Bioassay, Human) Bioassay Human
FY Mao, YP Lv, CJ Hao, YS Teng, YG Liu, P Cheng, SM Yang, W Chen, T Liu, QM Zou, R Xie, JY Xu, Y Zhuang Helicobacter pylori-induced Rev-erb&amp;alpha fosters gastric bacteria colonization by impairing host innate and adaptive defense Cellular and Molecular Gastroenterology and Hepatology, 2021-03-03;0(0):. 2021-03-03 [PMID: 33676046] (Bioassay, Human) Bioassay Human
H Zhang, Y Zheng, Y Pan, C Lin, S Wang, Z Yan, L Lu, G Ge, J Li, YA Zeng, J Chen A mutation that blocks integrin alpha4beta7 activation prevents adaptive immune-mediated colitis without increasing susceptibility to innate colitis BMC Biol., 2020-06-10;18(1):64. 2020-06-10 [PMID: 32522281] (Bioassay, Human) Bioassay Human
L Li, MW Shirkey, T Zhang, Y Xiong, W Piao, V Saxena, C Paluskievi, YS Lee, N Toney, BM Cerel, Q Li, T Simon, KD Smith, KL Hippen, BR Blazar, R Abdi, JS Bromberg The lymph node stromal laminin alpha 5 shapes alloimmunity J. Clin. Invest., 2020-05-01;0(0):. 2020-05-01 [PMID: 32017712] (Bioassay, Human) Bioassay Human
Show All 33 Publications.

Reviews for CCL21/6Ckine (366-6C) (0)

There are no reviews for CCL21/6Ckine (366-6C). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for CCL21/6Ckine (366-6C) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional CCL21/6Ckine Products

Blogs on CCL21/6Ckine.

Meningeal lymphatics: recent discovery defying the concept of central nervous system 'immune privilege'
By Jennifer Sokolowski, MD, PhD. Identification and characterization of meningeal lymphaticsThe recent discovery of a lymphatic system in the meninges surrounding the brain and spinal cord has spurred a surge of int...  Read full blog post.

Read our latest blog and use the new citation tool on bio-techne.com

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human CCL21/6Ckine Protein and receive a gift card or discount.

Bioinformatics

Gene Symbol CCL21
Uniprot